Skip to main content

Table 1 Patients’ demographics and preoperative clinical data

From: Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety

Variable Control (number = 49) EPO (number = 49) P value
Age (years) 62 ± 10 63 ± 10 0.880
Female 24 (49) 20 (41) 0.417
BMI (kg/m2) 24 ± 4 24 ± 3 0.528
Operation    
   MVR + TAP 6 (12) 8 (16) 0.564
   Multi valve 22 (45) 20 (41) 0.683
   Valve + CABG 8 (16) 7 (14) 0.779
   Bentall 13 (27) 14 (29) 0.821
   Redo 6 (12) 4 (8) 0.505
NYHA    
   I-II 42 (86) 43 (88) 0.766
   III-IV 7 (14) 6 (12)  
EuroSCORE 5.1 ± 2.6 5.7 ± 2.5 0.299
DM 8 (16) 16 (33) 0.060
Hypertension 24 (49) 27 (55) 0.544
Chronic kidney disease 14 (29) 10 (20) 0.347
Chronic obstructive lung disease 2 (4) 0 (0) 0.495
Ejection fraction (%) 60 ± 13 60 ± 12 0.798
Preoperative eGFR 77 ± 30 83 ± 28 0.378
Preoperative CrCl <60 ml/min 21 (43) 17 (35) 0.407
Medication    
   β-blockers 18 (38) 14 (29) 0.350
   CCB 17 (35) 13 (27) 0.344
   ACEi 17 (35) 12 (25) 0.240
   ARB 16 (33) 13 (27) 0.464
   Diuretics 28 (58) 28 (57) 0.906
Preoperative hematocrit (%) 38 ± 6 39 ± 4 0.375
  1. Values are mean ± SD or number of patients (%). ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; BMI, body mass index; CCB, calcium channel blockers; CrCl, creatinine clearance; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; Multi valve, more than two valve replacement; MVR, mitral valve replacement; NYHA, New York Heart Association Functional Classification; TAP, tricuspid annuloplasty; Valve + CABG, valvular replacement with coronary artery bypass grafting.